The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 8, 2005, Pages 1883-1889

  Chui, Stephen Y ^a   Clay, Timothy M ^a   Lyerly, H Kim ^a   Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; GASTRIN; HELICOBACTER PYLORI VACCINE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

CANCER PREVENTION; DISEASE ASSOCIATION; DRUG EFFICACY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STOMACH MUCOSA; SURVIVAL; VACCINE PRODUCTION;

ADENOCARCINOMA; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CANCER VACCINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS;

EID: 23844498720     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0775     Document Type: Review

References (83)

1. Hecht JR, Ajani JA, Michaeli D, et al. A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease. [abstract 1035]. Proc Am Soc Clin Oncol 2003;22:258.
2. Marshall J, Odogwu L, Hwang L, et al. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7.1/ICAM-1/LFA-3) alone, and sequentially with vaccinia-CEA (6D)-TRICOM and GM-CSF in patients with CEA-expressing carcinomas. [abstract 662]. Proc Am Soc Clin Oncol 2003;22:165.
3. Foon JA, John WK, Chakraobrty K, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999;17:2889-5.
4. Hertkorn C, Lehr A, Woelfel T, et al. Phase I trial of vaccination with autologous tumor-derived gp96 (oncophage) in patients after surgery for gastric cancer. [abstract 114]. Proc Am Soc Clin Oncol 2002;21:300.
5. Kimura H, Yonemura Y. Flow cytometric analysis of nuclear DNA content in advanced gastric cancer and its relationship with prognosis. Cancer 1981;67:2588-93.
6. Lee HS, Lee HK, Kim HS, et al. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46.
7. Ishii H, Gouchi A, Orita K. The enhancement of cell surface ICAM-I and HLA class I antigens in human gastric cancer cell lines by IFN-γ. Acta Med Okayama 1994;48:73-9.
8. Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer. Clin Cancer Res 2002;8:1767-71.
9. Lim SC. Fas-related apoptosis in gastric adenocarcinoma. Oncol Rep 2003;10:57-63.
10. Bennett MW, O'Connell J, O'Sullivan GC, et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999;44:156-62.
11. Ichihara F, Kono K, Takahashi A. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
12. Mukhopadhyay P. Gastric cancer and lymphoma. Gastroduodenal disease and Helicobacter pylori: Pathophysiology, Diagnosis and Treatment. In: Westblom TU, Czinn SJ, Nedrud JG, editors. Berlin: Springer-Verlag; 1999. p. 57-69.
13. Normura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120:977-81.
14. Martin-de-Argila C, Boixeda D, Redondo C, et al. Relation between histologie subtypes and location of gastric cancer and Helicobacter pylori. Scand J Gastroenterol 1997;32:303-7.
15. Meireles SI, Cristo EB, Carvalho AF, et al. Molecular classifiers for gastric cancer and nonmalignant diseases of the gastric mucosa. Cancer Res 2004;64:1255-65.
16. Parsonnett J. H pylori: the size of the problem. Gut 1998;43:S6-8.
17. Correa P, Fox J, Fontham E, et al. Helicobacter pylori and gastric carcinoma: serum antibody prevalence in populations with contrasting cancer risks. Cancer 1990;66:2569-74.
18. Sipponen P, Hyvarinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol Suppl 1993;196:3-6.
19. You WC, Zhang L, Gail MH, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000;92:1607-12.
20. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
21. Infection with Helicobacter pylori. In: IARC monographs on the evaluation of the carcinogenic risks to humans. Vol. 61. Schistosomes, liver flukes and Helicobacter pylori. Lyon (France): IARC; 1994. p. 177-241.
22. Mitchell HM. The epidemiology of Helicobacter pylori. Curr Top Microbiol Immunol 1999;241:11-30.
23. Parsonnet J, Shumely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999;282:2240-5.
24. Unge P. Antibiotic treatment of Helicobacter pylori infection. Curr Top Microbiol Immunol 1999;241:261-300.
25. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7.
26. Bauerfeind P, Garner R, Dunn B, et al. Synthesis and activity of Helicobacter pylori urease and catalase at low pH. Gut 1997;40:25-30.
27. Eaton KA, Brooks CL, Morgan DR, et al. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 1991;59:2470-5.
28. Leal-Herrera Y, Torres J, Perez-Perez G, et al. Serologic IgG response to urease in Helicobacter pylori infected persons from Mexico. Am J Trop Med Hyg 1999;60:587-92.
29. D'Elios MM, Manghetti M, De Carli M, et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997;158:962-7.
30. Massari P, Manetti R, Burroni D, et al. Binding of Helicobacter pylori cytotoxin to target cells. Infect Immun 1998;66:3981-4.
31. Molinari M, Galli C, Norais N, et al. Vacuoles induced by Helicobacter pylori toxin contain both the endosomal and lysosomal markers. J Biol Chem 1997;272:25339-44.
32. Molinari M, Salio M, Galli C, et al. Selective inhibition of II-dependent antigen presentation by Helicobacter pylori toxin VacA. J Exp Med 1998;187:135-40.
33. D'Elios MM, Manghetti M, De Carli M, et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997;158:962-7.
34. + cytotoxic T cell response and prolongs viral infection. J Infect Dis 1998;177:72-80.
35. Xiang ZY, Censini S, Bayeli PF, et al. Analysis and expression of VacA and CagA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immunol 1995;63:94-8.
36. Covacci A, Telford JL, Del Guidice G, et al. Helicobacter pylori, virulence and geography. Science 1999;284:1328-33.
37. Covacci A, Rappuoli R. Tyrosine phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 2000;191:587-92.
38. Xiang ZY, Bugnoli M, Ponzetto A, et al. Detection in an enzyme immunoassay of an immune response to a recombinant fragment of the 128 kilodalton protein (CagA) of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1993;12:739-45.
39. + Helicobacter pylori strains. J Clin Microbiol 1995;33:1496-500.
40. D'Elios MM, Manghetti M, Almerigogna F, et al. Different cytokine profile and antigen specificity repertoire in Helicobacter pylon specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol 1997;27:1751-5.
41. + T cell lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun 1998;66:5543-6.
42. Bamford KB, Fan X, Crowe SE, et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori infection have a T helper cell 1 phenotype. Gastroenterology 1998;114:482-92.
43. Saldinger PF, Porta N, Launois P, et al. Immunization of BALB/c mice with Helicobacter pylori urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology 1998;115:891-7.
44. Manttapallil JJ, Dandekar S, Canned DR, et al. A predominant Th1 type of immune response is induced early during acute Helicobacter pylori infection in rhesus macaques. Gastroenterology 2000;118:307-15.
45. Underdown BJ, Mestecky J. Mucosal immunoglobulins. Handbook of mucosal immunology. In: Ogra PL, Mesteck J, Lamm ME, Strober W, McGhee JR, Bienenstock J, editors. Boston: Academic Press, Inc.; 1994. p. 79.
46. Brandtzaeg P. Distribution and characteristics of mucosal immunoglobulin-producrng cells. In: Handbook of Mucosal Immunology. Ogra PL, Mestecky J, Lamm ME, Strober W, McGee JR, Bienenstock J. San Diego, CA: Academic; 1994, p. 251-62.
47. Lee CKm, Weltzin Rm, Thomas WD, et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter pylori. J Infect Dis 1995;172:161-72.
48. Pappo J, Thomas WD, Kabok Z, et al. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect Immun 1995;63:1246-52.
49. Czim SJ, Cai A, Nedrud JG, et al. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993;11:637-42.
50. Ferrero RL, Thiberge JM, Labigne A. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter pylori. Gastroenterology 1997;113:185-94.
51. Weltzin R, Kleanthous H, Guirakhoo F, et al. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 1997;15:370-6.
52. Ermak TH, Ding R, Ekstein B, et al. Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria. Gastroenterology 1997;113:1118-28.
53. Sutton P, Wilson Jm, Kosaka T, et al. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 2000;78:28-30.
54. Ermak TH, Giannasca PJ, Nichols R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II restricted responses. J Exp Med 1998;188:2277-88.
55. Atherton JC, Tham KT, Peek RM, et ai. Density of Helicobacter pylori infection in vivo as assessed by quantitative culture and histology. J Infect Dis 1996;174:552-6.
56. Foxs JG, Blanco M, Murphy JC, et al. Local and systemic immune responses in murine Helicobacter felis active chronic gastritis. Infect Immun 1993;61:2309-15.
57. + T cell clones from peripheral blood and gastric biopsies. Infect Immun 1995;63:1102-6.
58. D'Elios MM, Manghetti M, De Carli M, et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997;158:962-7.
59. Mohammadi M, Czinn S, Redline R, Nedrud J. Helicobacter -specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J Immunol 1996;156:4729-38.
60. Pappo J, Torrey D, Castriotta L, et al. Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun 1999;67:337-41.
61. Croitoru K. Immunomodulation of Helicobacter pylori infection. Can J Gastroenterol 1999;13:237-41.
62. Saldinger PE, Porta N, Launois P, et al. Immunization of BALB/C mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterol 1998;115:891-7.
63. Gobert AP, McGee DJ, Akhtar M, et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc Natl Acad Sci U S A 2001;98:13844-9.
64. Ramarao N, Gray-Owen SD, Backert S, et al. Helicobacter pylori inhibits phagocytosis by professional phagocytes involving type IV secretion components. Mol Microbiol 2000;37(6):1389-404.
65. Allen LA, Schlesigner LS, Rang B. Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages. J Exp Med 2000;191:115-28.
66. Gerbert B, Fischer W, Weiss E, et al. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 2003;301:1099-102.
67. Boncristiano M, Paccani SR, Barone S, et al. The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med 2003;198:1887-97.
68. Ricci VA, Sommi P, Fiocca R, et al. Helicobacter pylori vacuolating toxin accumulates within the endosomal vacuolar compartment of cultured gastric cells and potentiates the vacuolating activity of ammonia. J Pathol 1997;183:453-9.
69. Blanchard TG, Yu F, Hsieh C, et al. Severe inflammation and reduced bacteria load in murine Helicobacter infection caused by lack of phagocyte oxidase activity. J Infect Dis 2003;187:1609-15.
70. Karnes WE, Smaloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophie body gastritis. Gastroenterology 1991;101:167-74.
71. Perez-Perez GI, Shepherd VL, Morrow JD, et al. Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun 1995;63:1183-7.
72. Lee SK, Stack A, Katowitsch E, et al. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003;5:1345-56.
73. Akopyanz N, Bukanov NO, Westblom TU, et al. PCR-based RFLP analysis of DNA sequence diversity in the gastric pathogen Helicobacter pylori. Nucleic Acids Res 1992;20:6621-5.
74. Israel DA, Salama N, Krishna U, et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc Natl Acad Sci U S A 2001;98:14625-30.
75. Wang G, Ge Z, Rasko DA, et al. Lewis antigens in Helicobacter pylori: biosynthesis and phase variation. Mol Microbiol 2000;36:1187-96.
76. Hatzifori C, Wren BW, Morrow WJW. Helicobacter pylori vaccine strategies: triggering a guy reaction. Immunol Today 2000;21:615-9.
77. Banerjee S, Medina-Fatimil A, Nichols R, et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002;51:634-40.
78. Kotloff KL, Sztein MB, Wasserman SS, et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001 Jun;69:3581-90.
79. Gomez-Duarte OG, Bumann D, Meyer TF, et al. The attenuated Salmonella vaccine approach for the control of Helicobacter pylori related diseases. Vaccine 1999;17:1667-73.
80. Li GQ, Chen MH, Zhu SL, et al. Therapeutic vaccination against Helicobacter pylori infection with attenuated recombinant Salmonella typhimurium urease B subunit and catalase in mice. Chin J Digest Dis 2004;5:72.
81. Hasan UA, Abai AM, Harper DR, et al. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 1999;229:1-22.
82. Kim SY, Don HJ, Jang MH, et al. Oral immunization with Helicobacter pylori loaded poly(D,L-lactide-co-glycolide) nanoparticles. Helicobacter 1999;4:33-9.
83. Sommer F, Wilken H, Faller G, et al. Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun 2004;72:1029-35.